Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies

REVISTA CLINICAL IMMUNOLOGY GERSON

Authors: Gerson Dierley Keppeke, Monica Simon Prado, Eunice Nunes, Sandro Felix Perazzio, Silvia Helena Rodrigues, Maria Lucia Gomes Ferraz, Edward K L Chan e Luis Eduardo Coelho Andrade

Abstract

Some HCV patients using ribavirin and interferon alpha (IFN-α) develop anti-rods and rings (RR) autoantibodies, the main target of which is inosine monophosphate dehydrogenase (IMPDH), the rate-determining enzyme in de novo GTP biosynthesis. In vitro inhibition of IMPDH by ribavirin induces RR formation. Here we investigate whether other commonly used drugs that interfere with GTP biosynthesis can induce RR structures in vitro and vivo and elicit generation of autoantibodies. HEp-2 cells treated for 24h with ribavirin, mycophenolic acid (MPA), azathioprine, methotrexate or acyclovir were positive for RR structures. However, adefovir, entecavir, tenofovir and lamivudine did not induce RR structures in these cells. Structures induced by ribavirin in HEp-2 cells are stable after 24h drug-washout, while structures induced by other drugs are relatively labile, disappearing within 2h. Looking at patients treated with these drugs, HCV patients treated with ribavirin (n=17) showed higher average percentage of RR-positive peripheral mononuclear cells than autoimmune patients treated with RR-inducing immunosuppressant drugs (n=21). Serum from 173 autoimmune patients who had been treated with MPA, azathioprine or methotrexate was tested for presence of anti-RR autoantibodies, and only one sample was found to be positive. Conversely, of 48 anti-RR autoantibody positive samples identified at Fleury Laboratories over 30months, 94% were from HCV patients treated with ribavirin plus IFN-α. These data indicate that RR structures can be induced by a variety of drugs in vitro and in vivo, but anti-RR autoantibody production is mostly restricted to HCV patients under ribavirin+IFN-α treatment.

DOI: 10.1016/j.clim.2016.10.004
 
 

 

 

Artigos Relacionados - Artigos Científicos

24 May 2017 17:05

Authors: Kaline M. C. Pereira  Atila G. A. Faria  Bernadete L. Liphaus  Adriana A. Jesus [ ... ]

Artigos Cientificos
24 May 2017 18:15

Authors: Natalia de Oliva Spolidoro Paschoal, Jamil Natour, Flavia S. Machado, Hilda [ ... ]

Artigos Cientificos
24 May 2017 17:05

Authors: Gerson Dierley Keppeke, Monica Simon Prado, Eunice Nunes, Sandro Felix Perazzio, Silvia [ ... ]

Artigos Cientificos

© 2013 - 2017 Universidade Federal de São Paulo - Unifesp

Rua Botucatu, 740 - Vila Clementino • CEP 04023-900 - São Paulo - SP

+55 11 5576 4848 Ramal 3071  •    ppg.reumato@unifesp.br